Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.
View/ Open
Date
2015-01-12Author
Girotti, MR
Lopes, F
Preece, N
Niculescu-Duvaz, D
Zambon, A
Davies, L
Whittaker, S
Saturno, G
Viros, A
Pedersen, M
Suijkerbuijk, BMJM
Menard, D
McLeary, R
Johnson, L
Fish, L
Ejiama, S
Sanchez-Laorden, B
Hohloch, J
Carragher, N
Macleod, K
Ashton, G
Marusiak, AA
Fusi, A
Brognard, J
Frame, M
Lorigan, P
Marais, R
Springer, C
Type
Journal Article
Metadata
Show full item recordAbstract
BRAF and MEK inhibitors are effective in BRAF mutant melanoma, but most patients eventually relapse with acquired resistance, and others present intrinsic resistance to these drugs. Resistance is often mediated by pathway reactivation through receptor tyrosine kinase (RTK)/SRC-family kinase (SFK) signaling or mutant NRAS, which drive paradoxical reactivation of the pathway. We describe pan-RAF inhibitors (CCT196969, CCT241161) that also inhibit SFKs. These compounds do not drive paradoxical pathway activation and inhibit MEK/ERK in BRAF and NRAS mutant melanoma. They inhibit melanoma cells and patient-derived xenografts that are resistant to BRAF and BRAF/MEK inhibitors. Thus, paradox-breaking pan-RAF inhibitors that also inhibit SFKs could provide first-line treatment for BRAF and NRAS mutant melanomas and second-line treatment for patients who develop resistance.
Collections
Subject
Cell Line, Tumor
Animals
Humans
Mice
Mice, Nude
Melanoma
Melanoma, Experimental
Phenylurea Compounds
Pyrazines
Proto-Oncogene Proteins B-raf
src-Family Kinases
Antineoplastic Agents
Protein Kinase Inhibitors
Xenograft Model Antitumor Assays
Gene Expression Regulation, Neoplastic
Drug Resistance, Neoplasm
Female
Research team
Gene & Oncogene Targeting
Molecular Drug Resistance
Language
eng
Date accepted
2014-11-07
License start date
2015-01
Citation
Cancer cell, 2015, 27 (1), pp. 85 - 96
Publisher
CELL PRESS